Literature DB >> 16520272

Differences in gene expression between noninvasive and invasive transitional cell carcinoma of the human bladder using complementary deoxyribonucleic acid microarray: preliminary results.

Essam Elsamman1, Tomoharu Fukumori, Ashraf A Ewis, Nermin Ali, Kazuaki Kajimoto, Yasuo Shinohara, Mitsuru Ishikawa, Masayuki Takahashi, Masa-Aki Nishitani, Yoshinobu Baba, Hiro-omi Kanayama.   

Abstract

This study was performed to identify differences in gene expression between superficial noninvasive and invasive transitional cell carcinoma (TCC) of the bladder in human beings. We used complementary deoxyribonucleic acid microarrays containing 14,551 different genes to analyze gene expression among 6 cases of superficial and 6 cases of invasive TCC of the bladder to identify differences in gene expression, which might explain differences in the biology and clinical outcomes of these histologic subtypes of TCC. Quantitative real-time polymerase chain reaction was performed for selected genes to validate the microarray data. Significant up-regulation of 40 genes was associated with cases of superficial noninvasive, but not in invasive, TCC of the urinary bladder. This effect included genes involved in epithelial cell dedifferentiation and keratinization, as well as genes related to cell cycle, cell adhesion, transcription, and apoptosis. Conversely, significant up-regulation of 34 genes was associated with cases of invasive TCC, but not in superficial TCC, including genes related to extracellular matrix degradation, immune responses, cell cycling, and angiogenesis. This study shows the usefulness of complementary deoxyribonucleic acid microarray technology for identifying differences in gene expression among different histotypes of bladder cancer.

Entities:  

Mesh:

Year:  2006        PMID: 16520272     DOI: 10.1016/j.urolonc.2005.07.011

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  7 in total

1.  Gene expression profiling of chemically induced rat bladder tumors.

Authors:  Ruisheng Yao; Yijun Yi; Clinton J Grubbs; Ronald A Lubet; Ming You
Journal:  Neoplasia       Date:  2007-03       Impact factor: 5.715

2.  Combination of a novel gene expression signature with a clinical nomogram improves the prediction of survival in high-risk bladder cancer.

Authors:  Markus Riester; Jennifer M Taylor; Andrew Feifer; Theresa Koppie; Jonathan E Rosenberg; Robert J Downey; Bernard H Bochner; Franziska Michor
Journal:  Clin Cancer Res       Date:  2012-01-06       Impact factor: 12.531

Review 3.  Clinical states model for biomarkers in bladder cancer.

Authors:  Andrea B Apolo; Matthew Milowsky; Dean F Bajorin
Journal:  Future Oncol       Date:  2009-09       Impact factor: 3.404

4.  Pathological significance and prognostic significance of FES expression in bladder cancer vary according to tumor grade.

Authors:  Akihiro Asai; Yasuyoshi Miyata; Kosuke Takehara; Shigeru Kanda; Shin-Ichi Watanabe; Peter A Greer; Hideki Sakai
Journal:  J Cancer Res Clin Oncol       Date:  2017-09-26       Impact factor: 4.553

5.  Gene expression profiling in bladder cancer identifies potential therapeutic targets.

Authors:  Syed A Hussain; Daniel H Palmer; Wing-Kin Syn; Joseph J Sacco; Richard M D Greensmith; Taha Elmetwali; Vijay Aachi; Bryony H Lloyd; Puthen V Jithesh; John Arrand; Darren Barton; Jawaher Ansari; D Ross Sibson; Nicholas D James
Journal:  Int J Oncol       Date:  2017-03-02       Impact factor: 5.650

6.  Down-regulated claudin-7 immunoexpression in urothelial carcinoma of the urinary bladder.

Authors:  Mohamed Gadelmoula; Tomoharu Fukumori; Hiroyoshi Nakatsuji; Mohammed Elgammal; Kazunori Toida; Hiro-Omi Kanayama
Journal:  Arab J Urol       Date:  2013-05-28

7.  Cytokeratin 15 marks basal epithelia in developing ureters and is upregulated in a subset of urothelial cell carcinomas.

Authors:  Guangping Tai; Parisa Ranjzad; Fiona Marriage; Samrina Rehman; Helen Denley; Jill Dixon; Karen Mitchell; Philip J R Day; Adrian S Woolf
Journal:  PLoS One       Date:  2013-11-18       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.